insights_auto
GIS niyə bu qədər qalxıb: 3,18%?
Ətraflı araşdırınchevron_right
GIS:ETR
Gilead Sciences, Inc
133,64 €
arrow_upward
+3,18%(+4,12) 1D
9 okt, 17:35:39 GMT+2 · EUR
search
Bütün simvollar
| Simvol | Qiymət | Dəyişiklik | % Dəyişiklik |
|---|
insights_autoGIS üçün ən vacib statistik məlumatlar yaradılır...
Açın
131,64 €
Yüksək
133,64 €
Aşağı
130,76 €
Bazar kapitalizasiyası
187,44 mlrd
Ortalama həcm
683,00
Həcm
3,01K
52 həftəlik ən yüksək
136,24 €
52 həftəlik ən aşağı
98,96 €
İşçilərin sayı
17K
Açın
131,64 €
Yüksək
133,64 €
Aşağı
130,76 €
Bazar kapitalizasiyası
187,44 mlrd
Ortalama həcm
683,00
Həcm
3,01K
52 həftəlik ən yüksək
136,24 €
52 həftəlik ən aşağı
98,96 €
İşçilərin sayı
17K
Xəbər materialları
Veb mənbələri və xəbər partnyorlarından
Yahoo Finance
·
2 saat öncə
Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive?
Trefis
·
1 gün öncə
Why Is Everyone Ignoring Gilead Stock’s High Cash Yield?
AD HOC NEWS
·
1 gün öncə
Gilead Sciences stock gains 2.23 percent after-hours to EUR 134.13
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Gilead Sciences, Inc haqqında
Baş İcraçı DirektorDaniel O'Day
İşçilər17K
Təsis Tarixi22 iyn 1987
Baş OfisFoster City, Kaliforniya, Amerika Birləşmiş Ştatları
Sektor-
Veb-saytgilead.com